Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms
Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2016-08, Vol.12 (16), p.1877 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 16 |
| container_start_page | 1877 |
| container_title | Future oncology (London, England) |
| container_volume | 12 |
| creator | Rogowski, Wojciech Wachuła, Ewa Lewczuk, Anna Buscombe, John R Seklecka, Nina Sankowski, Artur Ćwikła, Jarosław B |
| description | Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Results: Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Conclusion:90Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes. |
| doi_str_mv | 10.2217/fon-2016-0031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2275269957</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275269957</sourcerecordid><originalsourceid>FETCH-proquest_journals_22752699573</originalsourceid><addsrcrecordid>eNqNij1PBCEURYnRxPWjtH-JNQoMM0hpdI2Fic02VhuWfehsmMcITDb-eyn8AeYW996cw9iNFHdKSXMfEnEl5MCF6OQJW0mjNX_ohDxtWxvLh8Hqc3ZRykEIbbperNjyluiTV8wTYAijd_4HUgArPvjz--axZQ0jwezqiFQLHMf6BZQoY0Ff3S5iY-QzNsGDoz2UycUIu3TECIRLTkj75PNI2G6aoytTuWJnwcWC1399yW5f1punVz7n9L1gqdtDWjI1tFXK9Gqwtjfd_6xfBIlSdg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275269957</pqid></control><display><type>article</type><title>Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms</title><source>PubMed Central</source><creator>Rogowski, Wojciech ; Wachuła, Ewa ; Lewczuk, Anna ; Buscombe, John R ; Seklecka, Nina ; Sankowski, Artur ; Ćwikła, Jarosław B</creator><creatorcontrib>Rogowski, Wojciech ; Wachuła, Ewa ; Lewczuk, Anna ; Buscombe, John R ; Seklecka, Nina ; Sankowski, Artur ; Ćwikła, Jarosław B</creatorcontrib><description>Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Results: Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Conclusion:90Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2016-0031</identifier><language>eng</language><publisher>London: Future Medicine Ltd</publisher><subject>Cancer therapies ; Chemotherapy ; Dosimetry ; Medical prognosis ; Metastasis ; Neuroendocrine tumors ; Pancreatic cancer ; Peptides ; Quality of life ; Response rates ; Small intestine</subject><ispartof>Future oncology (London, England), 2016-08, Vol.12 (16), p.1877</ispartof><rights>Copyright Future Medicine Ltd Aug 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Rogowski, Wojciech</creatorcontrib><creatorcontrib>Wachuła, Ewa</creatorcontrib><creatorcontrib>Lewczuk, Anna</creatorcontrib><creatorcontrib>Buscombe, John R</creatorcontrib><creatorcontrib>Seklecka, Nina</creatorcontrib><creatorcontrib>Sankowski, Artur</creatorcontrib><creatorcontrib>Ćwikła, Jarosław B</creatorcontrib><title>Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms</title><title>Future oncology (London, England)</title><description>Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Results: Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Conclusion:90Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.</description><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Dosimetry</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Neuroendocrine tumors</subject><subject>Pancreatic cancer</subject><subject>Peptides</subject><subject>Quality of life</subject><subject>Response rates</subject><subject>Small intestine</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNij1PBCEURYnRxPWjtH-JNQoMM0hpdI2Fic02VhuWfehsmMcITDb-eyn8AeYW996cw9iNFHdKSXMfEnEl5MCF6OQJW0mjNX_ohDxtWxvLh8Hqc3ZRykEIbbperNjyluiTV8wTYAijd_4HUgArPvjz--axZQ0jwezqiFQLHMf6BZQoY0Ff3S5iY-QzNsGDoz2UycUIu3TECIRLTkj75PNI2G6aoytTuWJnwcWC1399yW5f1punVz7n9L1gqdtDWjI1tFXK9Gqwtjfd_6xfBIlSdg</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Rogowski, Wojciech</creator><creator>Wachuła, Ewa</creator><creator>Lewczuk, Anna</creator><creator>Buscombe, John R</creator><creator>Seklecka, Nina</creator><creator>Sankowski, Artur</creator><creator>Ćwikła, Jarosław B</creator><general>Future Medicine Ltd</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20160801</creationdate><title>Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms</title><author>Rogowski, Wojciech ; Wachuła, Ewa ; Lewczuk, Anna ; Buscombe, John R ; Seklecka, Nina ; Sankowski, Artur ; Ćwikła, Jarosław B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_22752699573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Dosimetry</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Neuroendocrine tumors</topic><topic>Pancreatic cancer</topic><topic>Peptides</topic><topic>Quality of life</topic><topic>Response rates</topic><topic>Small intestine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rogowski, Wojciech</creatorcontrib><creatorcontrib>Wachuła, Ewa</creatorcontrib><creatorcontrib>Lewczuk, Anna</creatorcontrib><creatorcontrib>Buscombe, John R</creatorcontrib><creatorcontrib>Seklecka, Nina</creatorcontrib><creatorcontrib>Sankowski, Artur</creatorcontrib><creatorcontrib>Ćwikła, Jarosław B</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rogowski, Wojciech</au><au>Wachuła, Ewa</au><au>Lewczuk, Anna</au><au>Buscombe, John R</au><au>Seklecka, Nina</au><au>Sankowski, Artur</au><au>Ćwikła, Jarosław B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms</atitle><jtitle>Future oncology (London, England)</jtitle><date>2016-08-01</date><risdate>2016</risdate><volume>12</volume><issue>16</issue><spage>1877</spage><pages>1877-</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Results: Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Conclusion:90Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.</abstract><cop>London</cop><pub>Future Medicine Ltd</pub><doi>10.2217/fon-2016-0031</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2016-08, Vol.12 (16), p.1877 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_journals_2275269957 |
| source | PubMed Central |
| subjects | Cancer therapies Chemotherapy Dosimetry Medical prognosis Metastasis Neuroendocrine tumors Pancreatic cancer Peptides Quality of life Response rates Small intestine |
| title | Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T05%3A02%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20efficacy%20of%2090Y-DOTATATE%20in%20patients%20with%20nonresectable%20pancreatic%20and%20small%20bowel%20neuroendocrine%20neoplasms&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Rogowski,%20Wojciech&rft.date=2016-08-01&rft.volume=12&rft.issue=16&rft.spage=1877&rft.pages=1877-&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2016-0031&rft_dat=%3Cproquest%3E2275269957%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2275269957&rft_id=info:pmid/&rfr_iscdi=true |